The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges

The transient receptor potential ankyrin 1 (TRPA1) channel is a calcium-permeable nonselective cation channel in the plasma membrane that belongs to the transient receptor potential (TRP) channel superfamily. Recent studies have suggested that the TRPA1 channel plays an essential role in the develop...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 10; p. 1253
Main Authors Wang, Zhen, Ye, Di, Ye, Jing, Wang, Menglong, Liu, Jianfang, Jiang, Huimin, Xu, Yao, Zhang, Jishou, Chen, Jiangbin, Wan, Jun
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 18.10.2019
Subjects
arrhythmia
atherosclerosis
heart failure
myocardial fibrosis
myocardial ischemia–reperfusion injury
Pharmacology
TRPA1 channel
Online AccessGet full text

Cover

More Information
Summary:The transient receptor potential ankyrin 1 (TRPA1) channel is a calcium-permeable nonselective cation channel in the plasma membrane that belongs to the transient receptor potential (TRP) channel superfamily. Recent studies have suggested that the TRPA1 channel plays an essential role in the development and progression of several cardiovascular conditions, such as atherosclerosis, heart failure, myocardial ischemia–reperfusion injury, myocardial fibrosis, arrhythmia, vasodilation, and hypertension. Activation of the TRPA1 channel has a protective effect against the development of atherosclerosis. Furthermore, TRPA1 channel activation elicits peripheral vasodilation and induces a biphasic blood pressure response. However, loss of channel expression or blockade of its activation suppressed heart failure, myocardial ischemia–reperfusion injury, myocardial fibrosis, and arrhythmia. In this paper, we review recent research progress on the TRPA1 channel and discuss its potential role in the cardiovascular system.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Martin C. Michel, Johannes Gutenberg, University Mainz, Germany
Reviewed by: Philip Aaronson, King’s College London, United Kingdom; Jennifer Beth Stott, University of London, United Kingdom
These authors have contributed equally to this work
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.01253